Cachectic Cancer Patients: Immune to Checkpoint Inhibitor Therapy?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 30018117.
- Also identified by DOI 10.1158/1078-0432.CCR-18-1847 and PMC identifier 6279566.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Immune checkpoint inhibition is dramatically improving patient outcomes in diverse cancers, many of which responded poorly to traditional cytotoxic agents. Drivers of heterogeneous response to immune checkpoint therapy are poorly characterized. Cachectic cancer patients exhibit elevated pembrolizumab clearance and poor response, highlighting the immense therapeutic challenge posed by cancer cachexia.<i>See related article by Turner et al., p. 5841</i>.
Medical subject headings
- Cachexia
- Neoplasms